IDO1 and melanoma: In the present report, the immune and clinical responses to an IDO-silenced DC vaccine were investigated in a patient with advanced melanoma pretreated with ipilimumab, a monoclonal IgG1 anti-CTLA-4 neutralizing antibody [17].